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Introduction
Only two of the approximately twenty alcohol-sensitizing
compounds reported have received widespread therapeutic use,
disulfiram (tetraethylthiuram disulfide) and calcium carbimide
(citrated calcium carbimide.) Of these, only disulfiram has
been approved for distribution in the United States (1).
Sellers et al. (2) reported that ninety percent of physicians
in private practice in this country prescribe drugs for the
treatment of alcoholism, with disulfiram the drug of choice for
aversion therapy. The goal of alcohol-sensitizing drug treat-
ment is to deter alcohol consumption, thus allowing the patient
to participate in accepted behavioral and psychosocial therapy
(3).
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Disulfiram (Antabuse , Ayerst Laboratories) was first
noted to cause an adverse reaction with alcohol ingestion by
Hald and Jacobsen in 1948 (2). Originally, disulfiram was
believed to be inert unless alcohol was present, however,
several investigations have indicated the possibility of side
effects not related to the ingestion of alcohol (1-5).
There is growing concern about potential nutrient-drug
interactions among physicians, nutritionists, and pharmacists.
Although alterations in serum cholesterol levels, pyridoxine
levels, and tryptophan levels have been implicated with the
use of disulfiram no studies to date have investigated the
nutritional status of the alcoholic in treatment, receiving
disulfiram therapy. Such information is vital in insuring the
optimal nutritional well being of the alcoholic receiving
disulfiram treatment.
The present placebo-controlled, double-blind, study was
undertaken specifically to examine the short-term effects (21
days) of disulfiram (Antabuse) therapy on the nutritional
status and serum cholesterol levels (total cholesterol, TC;
high-density lipoprotein cholesterol, HDL-C; and low-density
lipoprotein cholesterol, LDL-C) of abstaining alcoholics.
Increased knowledge pertaining to the use of disulfiram
(Antabuse) in therapeutic doses (250 mg per day) will aid in
determination of concrete benefits and (or) hazards in short-
term and long-range therapy.
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Review of Literature
Alcohol-Disulf iram Interaction
Disulfiram acts to inhibit aldehyde dehydrogenase (ALDH),
the enzyme necessary for the oxidation of acetaldehyde to
acetic acid. This inhibition develops approximately twelve
hours after administration of the drug and is irreversible (5,
6). Regeneration of ALDH activity depends on d_e nova enzyme
synthesis, thus the alcohol-sensitizing effect of disulfiram
can occur up to ten days after cessation of the drug (1,3,5-8).
The aversion effect for ethanol is produced when the disulfiram
treated individual ingests alcohol and the blood acetaldehyde
levels are raised producing the following: dyspnea, tachypnea,
tachycardia, flushing, hypotension, headache, nausea, and
vomiting (1,3-5,7,9-11).
Disulfiram Related Side-Effects
Several experimental studies have suggested that during
short-term administration of therapeutic doses of disulfiram
(250-500 mg per day) the alcoholic may experience a variety
of side effects not related to alcohol intake. Peachey and
Naranjo (3) in an extensive report on the role of drugs in
the treatment of alcoholism, discuss several possible effects
from the administration of disulfiram: Inhibition of ALDH,
dopamine-B-hydroxylase and hepatic mixed-function oxidases
(MFO), drug-induced neuropathy, hepatotoxicity , increased serum
cholesterol, antithyroid action, neuroendocrine toxicity, and
dysmorphogenic effects (hemoglobin, leucocytes, erythrocytes).
Sellers et al. (2) reported that disulfiram treatment could
result in hepatotoxicity , hypertension, peripheral neuropathy,
and increase in serum cholesterol levels.
Serum cholesterol
Major and Goyer (12) observed an elevation of serum cho-
lesterol levels in alcoholic patients receiving 250 mg or
500 mg disulfiram daily for six weeks. Serum cholesterol in
creased significantly (193 +/- 16.4 to 227.2 +/- 17.2 mg/dl)
after three weeks in those patients receiving 500 mg of disul-
firam daily. No statistically significant changes in serum
cholesterol were reported after administration of 250 mg of
disulfiram daily for three weeks to eight male alcoholics.
Determination of the effect of short-term (three weeks) di-
sulfiram therapy on lipid subfractions was not done in these
subjects. However, when pyridoxine was administered with
disulfiram, serum cholesterol decreased markedly suggesting
alterations in pyridoxine metabolism.
Carbon disulfide, the final metabolite of disulfiram, has
been shown to produce hypercholesterolemia (9,12). An increase
in arteriosclerotic cardiovascular disease from chronic carbon
disulfide exposure has been observed in animals and humans
(viscose rayon workers) (12). Increased serum cholesterol
levels in humans receiving disulfiram are hypothesized to be
a result of carbon disulfide induced pyridoxine deficiency
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(5,12,13,14). Toxic effects can be caused by 30 to 60 mg/m
carbon disulfide in the atmosphere which is roughly equivalent
to 125 to 250 mg of disulfiram per day (12). Carbon disulfide
reacts with pyridoxine resulting in a pyridoxine deficiency
(12-15), suggesting that disulfiram may have a similar effect.
But, the mechanism involved in the relationship of increased
serum cholesterol to pyridoxine deficiency is unclear.
In an investigation by Perier et al. (16) alcoholics re-
ceiving disulfiram and a challenge dose of alcohol daily during
a four week detoxification program followed by a weekly dose
of disulfiram for one year demonstrated an increase in serum
cholesterol (mean-235 mg/dl at 4 weeks to 263 mg/dl at 12 mo.,
baseline range-135 to 231 mg/dl), increase in LDL-C (mean-
168 mg/dl at 4 weeks to 218 mg/dl at 12 mo.), and a decrease in
HDL-C (mean-61 mg/dl at 4 weeks to 47 mg/dl at 12 mo.), al-
though this latter lipid subfraction was still significantly
high. However, the effects of the alcohol challenge and
effects of disulfiram in this study are difficult to seperate.
Rogers and Naseem (17) added 15 mg of disulfiram (per
kg of body weight) daily to the diet of twenty Sprague-Dawley
rats to elucidate the mechanism of disulf iram-induced hypercho-
lesterolemia. Serum cholesterol increased twenty-five percent
after three weeks of disulfiram treatment with a four-fold
elevation of hepatic HMG-CoA (3-hydroxy-3-methyl-glutaryl co-
enzyme A) reductase, the rate limiting enzyme involved in
cholesterol biosynthesis. This study clearly showed that the
increase in serum cholesterol was not due to variance of
dietary intake between test groups and suggested that chronic
administration of disulfiram might increase the risk of athero-
sclerosis and bilary complications.
Triglycerides
"Alcoholic Hypertriglyceridemia" from active alcohol use
and subsequent decrease in triglyceride (TG) levels with ab-
stinence, has been extensively reported in the literature (8,
18-20). However, Mach and Janik (13) found a significant ele-
vation of hepatic tissue TG and blood serum TG and cholesterol
in male Wistar rats after six weeks of disulfiram administra-
tion (150 mg/kg body weight/day), suggesting a need for further
study of the effect of disulfiram therapy on triglycerides.
Neurological changes
Mogens et al., (15) reported that disulfiram treatment
resulted in subnormal serum tryptophan levels after admin-
istration of an oral load of L-tryptophan (100 mg/kg body
weight). Serum tryptophan levels six hours after load were
11.9 +/- 1.2 mg/dl in disulfiram treated alcoholics and
14.8 +/- 0.7 mg/dl in non-treated abstaining alcoholics. No
differences in fasting serum tryptophan levels were observed,
suggesting that disulfiram treated individuals had more rapid
removal of tryptophan, an amino acid essential for normal
neuromuscular activity, from the blood. Neurological abnor-
malities have been reported after a few days of disulfiram
therapy with some symptoms surfacing after five years of
continual usage. However, most symptoms of peripheral neuro-
pathy begin four to six months after initiation of disulfiram
therapy (15,21,22). Worner (21) found that most patients who
developed peripheral neuropathy (symptomatic of pyridoxine and
thiamin deficiency) after one year of 250 mg disulfiram daily,
could resolve the adverse effects with decrease of daily dose
to 125 mg. These patients were receiving 300 mg thiamin, 50 mg
pyridoxine, and one multi-vitamin daily, which may have been
the primary cause of overt symptom resolution rather than
decreased dosage of disulfiram.
Cardiomyopathy and generalized myopathy
Major et al. (23) found in their investigation on the ef-
fects of prolonged disulfiram treatment in Rhesus monkeys, a
marked increase in plasma dopamine-B-hydroxylase (50% increase
after six weeks administration of 300 mg/kg body weight), the
enzyme necessary for conversion of dopamine to norepinephrine.
Disulfiram, as an irreversible inhibitor of aldehyde dehydro-
genase, significantly raises blood acetaldehyde, an effective
releasor of catecholamine. Thus, this study suggests that
disulfiram may directly effect the sympathetic nervous system
by increasing sympathetic activity, increasing both diastolic
and systolic blood pressure, and prolonging the possible ef-
fects of malnutrition and (or) alcoholism on the development of
cardiomyopathy (23-25).
Of interest is an investigation by Ekvarn et al. (26) on
30 Sprague-Dawley rats given 120 mg disulf iram/kg body weight
daily in water suspension and 30 controls receiving water only.
Myocardial degeneration in disulfiram treated rats was charac-
terized by swelling, disintegration and fatty infiltration of
the muscle fibers, as was expected. In addition, degenerative
changes in biceps, triceps brachii, quadriceps, and gastrocne-
mius muscles were observed in all animals receiving disulfiram
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for either seven or fourteen days.
Effects of Alcohol on Nutritional Status
Coronary heart disease
The relationship between alcohol and increased high-
density lipoprotein cholesterol (HDL-C) levels has been the
subject of many recent investigations since this cholesterol
fraction is believed to be a positive factor in the reduction
of risk for atherosclerosis. Alcohol consumption is positively
associated with HDL-C and appears to be dose related (18).
Data from the five populations participating in the Cooperative
Lipoprotein Phenotyping Study (18) shows a positive correlation
between high HDL-C levels and decreased incidence of coronary
heart disease (CHD). The results of this study, as reviewed
by Barborik, Gruchow, and Anderson (27), implicate low HDL-C
levels as the major predictive risk factor for CHD. However,
they also point out that to accurately analyze this relation-
ship between alcohol consumption and HDL-C levels, epidemio-
logical studies must be conducted on the extent of drinking in
the United States.
Data from the Framingham Study indicates that moderate
male drinkers (4-9 oz/week) had increased mean serum HDL-C
(50.14 mg/dl) compared to abstainers (45.69 mg/dl; 18).
Hulley, Mellon, and Dzvonik (28) report a U-shaped association
between alcohol consumption and CHD. This suggests that the
highest risk of CHD is found in abstainers and chronic abusers
with the lowest risk among moderate drinkers (up to approxi-
mately 3 "drinks" or 60 ml alcohol per day). However, epidemi-
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ological studies on blood lipids and coronary risk factors in
7,735 British and 520 Italian men, while showing a positive
correlation between daily alcohol intake and HDL-C levels,
found no statistical significance between daily alcohol intake
and decrease in positive risk factors; i.e., systolic and
diastolic blood pressure, body mass, cigarette smoking, and
physical activity (19,29). Even though moderate intake of
alcohol has been shown to increase HDL-C levels and fibrino-
lytic activity, both possible contributing factors to a lower
risk of CHD, Segel et al. (24) believe that certain individuals
may be unable to restrict their intake to moderate amounts of
alcohol, thus counteracting any significant prevention of CHD.
Lipid interactions
High-density lipoprotein cholesterol
The precise mechanisms by which alcohol influences
serum high-density lipoprotein cholesterol (HDL-C) are poorly
understood. Taskinen et al. (30), Marth et al. (31), and
Devenyi et al. (32) all concur that serum HDL-C levels fall to
control levels within one to three weeks of abstinence. Of
ninety-two patients entering an inpatient treatment facility
with a primary diagnosis of alcoholism, 20 percent of males and
57 percent of females evidenced high levels of serum HDL-C. At
the end of three weeks of abstinence only one subject was above
the upper limit of non-alcoholic control levels (controls-
males, 48 +/-14 mg/dl; females, 56 +/- 13 mg/dl; 33). In a
more recent study, Haskell et al. (34) found in their investi-
gation of HDL-C subfractions (HDL-C and HDL-C ) in moderate
2 3
drinkers (1.3 +/- 0.6 oz/day), a decrease in HDL-C mass after
3
five weeks abstinence (226.5 +/- 50.3 mg/dl from baseline;
261.5 +/- 49.0 mg/dl), and subsequent elevation in this sub-
fraction (265.0 +/- 49.2 mg/dl) after resumption of moderate
alcohol intake. They reported no significant effects from
either abstinence or return to alcohol intake on HDL-C mass,
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the supposed antiatherogenic subfraction. These findings
suggest that the proposed protective effect of alcohol on the
development of CHD is not mediated by subfraction HDL-C and
2
may be completely unrelated to HDL-C levels.
Triglycerides
Sixty to ninety percent of diagnosed alcoholics have
disturbed lipid metabolism affecting both cholesterol and tri-
glyceride (TG) levels (13). Alcohol enhances TG production in
the liver and excessive alcohol intake leads to hypertrigly-
ceridemia. Decreased lipid oxidation and increased lipogenesis
can be linked to alcohol oxidation and subsequent increase of
NADH (reduced form of nicotinamide adenine dinucleotide , NAD).
In the liver the NADH/NAD ratio favors the accumulation of
hepatic triglycerides by trapping fatty acids through raised
concentration of a-glycerophosphate (8). In agreement, were
the findings from an investigation by Erkelens and Brunzell
(20) undertaken to determine the etiology of hypertriglycer-
idemia as related to chronic alcohol intake. They evaluated
the TG level and removal rate before and after isocaloric re-
placement of alcohol for the basal diet. Endogenous TG removal
rate as related to lipoprotein lipase activated degredation was
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estimated by the heparin infusion method. Results indicated TG
production was affected, not rate of removal.
Type IV hyperlipoproteinemia (hypertriglyceridemia with
elevated very low density lipoproteins, VLDL) is associated
with excessive alcohol intake. Marth et al. (31) found that
while chronic alcoholics have increased TG levels over controls
(135 +/- 52 mg/dl vs. 104 +/- 29 mg/dl, respectively), TC and
LDL-C levels for alcoholics were significantly lower than con-
trols at baseline. This suggests that both hepatic TG and
intestinal VLDL production may be stimulated by chronic alcohol
intake (7,8,20,31).
Alcohol -Nutrient Interactions
The literature is abundant on the nutritional effects of
alcohol ingestion. Roe (35) states in Alcohol and the Diet
that the effect of alcohol on nutrition is a result of the hyp-
notic (psycho-active) effect of the drug leading to anorexia
and subsequent decrease in nutrient intake, interference with
nutrient utilization and absorption, direct toxic effect of
ethanol on tissues, and socioeconomic factors.
Eisenstein (7) has cited the following possible results
of excessive alcohol intake: glucose abnormalities (alcoholic
hypoglycemia and hyperglycemia), alcoholic hyperlipemia, he-
patomegaly, hemolytic anemia, acute pancreatitis, alcoholic
cirrhosis, low serum albumin (low immunocompetence) , amino acid
abnormalities (increased aromatic: tryptophan, phenyl-alanine,
tyrosine; depressed branched-chain: valine, leucine, isoleu-
cine), peripheral neuropathy, impaired nutrient absorption, and
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various other malabsorptive problems. All, or any, of these
may lead to a compromised nutritional status.
Abnormal Carbohydrate Metabolism
The effects of alcohol consumption on carbohydrate metabo-
lism have been well delineated during the past several years.
While many investigations have implicated chronic alcohol use
in decreased insulin response to oral glucose load some inves-
tigators suggest that a decrease in insulin production may be
secondary to decreased food intake (7).
More commonly seen is alcohol-induced hypoglycemia result-
ing from inhibition of gluconeogenesis . The inhibition process
(or site) in humans has not been defined, but animal studies
have positively correlated this inhibition to the reduction of
the NAD/NADH ratio related to alcohol metabolism. Thus, severe
decrease of nutrient intake leading to acute depletion of hepa-
tic glycogen (i.e., starvation) in concert with chronic alcohol
ingestion will impair hepatic glucose output in animals through
decreased gluconeogenesis (36).
Arkey, Veverbrants, and Abramson (37) reviewed five
cases related to alcohol-induced hypoglycemia. Each of these
patients were alcoholic diabetics receiving oral hypoglycemic
agents. In all of these patients alcohol seemed to enhance the
hypoglycemic effect; mean admitting non-fasting blood glucose
28.0 +/- 10.9 mg/dl. In a subsequent study on healthy males
given infusions of 15% ethyl alcohol in saline (2.0 ml/min
[236 mg ethyl alcohol/min] ) or saline for one hour, followed
by 0.1 units of glucagon-free insulin/kg/body weight, they
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found similar response among subjects in initial fall from
pretest glucose levels, but the rebound phase was signifi-
cantly depressed in the alcohol-insulin subjects. This study
indicates that alcohol interferes with the feed-back mechanisms
in insulin-induced hypoglycemia by prolonging dose effect and
retarding the normal rise in growth hormone secretion (7,37).
Malnutrition
In a recent publication, Roe (38) summarizes the etiolo-
gies of malnutrition in the alcoholic as complex and usually
associated with prior alcohol insult to the tissues, in combi-
nation with predisposition for certain nutritional deficien-
cies. Lieber (39), classifies malnutrition in alcoholism as
either primary or secondary; primary related to low intake of
nutrients due to (in accordance with Roe; 35,38) the anorexic
effect of alcohol, majority of limited resources spent on
alcohol, and low nutrient value of alcoholic bevererages. The
etiology of secondary malnutrition is related to a variety of
direct toxic effects of alcohol on the utilization and metab-
olism of nutrients.
The incidence of malnutrition among the alcoholic popula-
tion is undetermined. In a study of 62 middle-class alcoholic
patients, for whom the mean daily caloric contribution from
alcohol and non-alcohol foods was 2,000 kcal, only 12 percent
were less than ideal body weight (40). In agreement with this
study, Dickson et al. (41) found no severe nutritionnal de-
ficiencies in their investigation of visceral protein status in
twenty-five alcoholic inpatients, free of liver disease.
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However, several other investigations indicated an increased
incidence of protein malnutrition with multiple vitamin de-
ficiencies in lower-income alcoholic populations (40).
Protein . Utilizing anthropometric measurements (height/
weight index, triceps skin-fold, arm circumference), dietary
reviews, and serum analysis (albumin and transferrin) Simko et
al. (42) studied 102 alcoholics with and without liver disease
to determine nutritional status. They found that regardless of
adequate protein intake, alcoholics (without liver disease) had
markedly lower triceps skin-folds (7.4-7.6 mm vs. 12.1 mm in
abstainers), body weight (67.3-72.0 kg vs. 80.7 kg in ab-
stainers), and arm muscle circumference (264.0-264.2 mm vs.
297.0 mm in abstainers) than abstainers. These investigators
concluded that the poor nutritional status of alcoholics was
probably due to the direct toxic effects of alcohol and not
decreased intake of dietary calories. However, the prevalent
type of malnutrition seen in alcoholics is protein-calorie
malnutrition (PCM) often referred to as "Adult Marasmus."
Mendenhall et al. (43) found in an investigation of 284 pa-
tients with alcoholic hepatitis and 21 alcoholic patients with-
out liver involvement that all patients with liver disease and
62% of patients without evidenced some degree of either maras-
mus or kwashiorkor. With excessive chronic alcohol intake
approximately 20 to 25% of ingested alcohol may be metabolized
through a secondary pathway, the hepatic microsomal ethanol
oxidizing system (ME0S), delivering less than 7.1 kcal/gm and
believed to be an energy wasting process (7,35,44).
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Malnutrition is associated with altered RNA (ribonucleic
acid) metabolism and a decrease in the synthesis and secretion
of serum albumin, a major product of protein synthesis by the
liver (45). Serum albumin levels can be severely depressed
during trauma, malnutrition, and in conjunction with alcohol
related liver disease. To elucidate the effects of chronic
alcohol intake on albumin production, livers from fed and
fasted rabbits were measured for albumin synthesis 45 to 75
minutes after perfusion with 200 mg% alcohol. From this inves-
tigation, Rothschild, Oratz, and Schreiber (45) reported that
fasting depressed albumin production and disaggregated the en-
doplasmic bound polyribosomes. With refeeding, normal albumin
synthesis was associated with reggregation of bound proteins.
They observed the same results in chronic exposure to and sub-
sequent cessation of alcohol. Reduced albumin synthesis could
be reversed in the animal model by delivery of therapeutic
amounts of selected amino acids (arginine, ornithine, trypto-
phan, lysine, phenyl-alanine, alanine, threonine, proline, and
glutamine) to the liver. Chronic excessive alcohol use is the
primary cause of cirrhosis. However, the loss of hepatic par-
enchymal cells is responsible for impaired protein synthesis
(7). The effects of alcohol and fasting were similar in the
previous study which implies that alcohol may act as a pharma-
cologic fast (45).
Plasma amino acid abnormalities are not uncommon in alco-
holics as low protein intake associated with chronic alcohol-
ism depresses branched-chain amino acids (valine, leucine, and
15
isoleucine) and chronic alcoholism (without cirrhosis) tends to
increase the synthesis of these amino acids (39). The evidence
from several investigations indicates that alcohol related de-
pression of circulating branched-chain amino acids has a multi-
ple etiology. Shaw and Lieber (46) hypothesized, however, that
the primary cause of depressed branched-chain amino acids in
subjects without overt liver involvement, was dietary protein
deficiency.
Cardiomyopathy and generalized myopathy . Acute alcoholism
(chronic excessive alcohol intake) has been associated with
heart disease, and may result in alcoholic cardiomyopathy
(congestive cardiomyopathy) from the direct toxic effect of
alcohol on the heart (24). Rossi (25) argues, however, that
the relationship of alcohol abuse and cardiomyopathy is a
result of associated dietary deficiencies. The results of his
animal investigation indicate that continued exposure to
catecholamines (dopamine, epinephrine, and norepinephrine),
positively correlated with malnutrition, may play the major
role in increased development of cardiomyopathy.
Vitamin and Mineral Deficiencies
Deficiencies of folate, vitamin B-12 (cobalamin), thiamin,
and (or) vitamin B-6 (pyridoxine) have all been observed in
subjects with chronic alcohol consumption (7,35,38,40,42,44-
49). Decreased hepatic concentrations of vitamins are often
found in subjects with fatty liver due to decrease in storage
space as a result of deposition of fat and fibrous tissue.
Alcohol-induced catabolic losses of many vitamins and cellular
16
degeneration may also reduce hepatic concentrations. Thus,
vitamin and mineral deficiencies in alcoholics may result from
reduced intake, alterations in metabolism and absorption, de-
creased storage, and hyperexcretion (35,44,50). Halsted (48)
and Mezy (50) found that a significant number of alcoholic
subjects without overt liver disease (fatty liver or cirrhosis)
also evidenced malabsorption of folic acid, thiamin, and vita-
min B-12 without overt clinical signs of deficiency. This mal-
absorption seemed to correlate positively with recent excessive
alcohol intake, and resolved after two to three weeks absti-
nence combined with an adequate diet.
Folate deficiency . Folate deficiency (the vitamin most
commonly deficient in the alcoholic) results in intestinal
malabsorption. Eisenstein (7) and Roe (35) list the primary
histological changes occurring in the intestinal mucosa from
folate deficiency as shortened villi, reduced thickness of in-
testinal mucosa, and reversible megaloblastic changes in the
crypt epithelium of the villi. These changes will adversely
affect the absorption of other nutrients.
Jejunal uptake of folic acid (pteroylmonoglutamate [Pte-
Glu]) was studied in four chronic alcoholic patients; two
patients were maintained on a f olate-def icient diet with 256 gm
alcohol per day, one patient on a f olate-def icient diet with no
alcohol dose, and one patient on a f olate-adequate diet with
addition of 300 gm alcohol per day. Halsted (48) found that
3
compared to baseline values, jejunal uptake of H-Pte-Glu,
glucose, and sodium were decreased in f olate-def icient alcohol
17
dose patients. Water and sodium uptake were decreased and
3
uptake of H-PteGlu and glucose remained unchanged in single
challenge patients, indicating that dietary folate deficiency
in combination with chronic alcohol intake affects more than
one transport/absorption mechanism. Thus a cyclic effect may
occur whereby folate malabsorption contributes to folate de-
ficiency which in turn promotes intestinal malabsorption of
folate.
Values taken from a study by Mills et al . (47) on twenty-
three alcoholic patients, expressed as a percentage of the
recommended daily intake for groups of people in the United
Kingdom, showed 78% of patients with less than 60% of recom-
mended folate intake. They also reported low levels of serum
folate (43% of patients) and red cell folate (13% of patients).
In addition to low dietary intake of folate, alcohol exerts
a toxic effect on the gut reducing the absorption of several
vitamins including folate, thiamin, and vitamin B-12 (38).
Folate, vitamin B-12, and pyridoxine are necessary for
adequate cell replication. The primary cause of megaloblastic
anemia (commonly identified with chronic excessive alcohol use)
is folate deficiency with occasional secondary effect from
vitamin B-12 deficiency (50,35). The incidence of folate de-
ficiency in chronic alcoholism has been reported to be as high
as 87%, as determined by low serum folate levels (48,50), with
an increase of mean corpuscular volume MCV) found to be direct-
ly related to folate and (or) vitamin B-12 deficiencies.
Mildly elevated (100-110 cuu; normal value 87-103 cuu) MCV has
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been found in 25 to 96% of alcoholic patients and is frequently
used as a diagnostic marker of alcoholism (49,51).
Vitamin B-12 deficiency . Alcohol exerts a toxic effect
on the production of intrinsic factor, a protein synthesized
in the gastric mucosa and required for intestinal absorption of
vitamin B-12. But pernicious anemia, a "nutritional anemia"
caused by vitamin B-12 deficiency, is seen infrequently in
alcoholics (35,49,52). Apparently the major contribution of
vitamin B-12 deficiency is the enhancement of folate deficiency
through the methyl-folate-trap (49,52). This premise is based
on the hypothesis that as a result of vitamin B-12 deficiency,
folate is trapped and accumulates as 5-methyltetrahydrof olate
(5-methyl THF). And, etiologically implicates chronic alcohol
intake with pernicious, megaloblastic, and sideroblastic (ac-
cumulations of erythroid iron strongly associated with folate
deficiency) anemias (49).
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Materials and Methods
Patients
Thirty-one patients, admitted to the Chemical Problems
Treatment Unit (CPTU) of Colmery-O' Neil Veterans Administration
Medical Center for treatment of primary alcoholism, voluntarily
participated in this investigation. This study was approved by
the Committees on Research Involving Human Subjects at Kansas
State University and the Colmery-O' Neil Veterans Administration
Medical Center (CO-VMAC).
All consecutive admissions with a primary diagnosis of
alcoholism were considered and routine vitamin supplementation
was withheld until completion of diagnostic blood work. Sub-
jects were alcohol and abuse drug free for a minimum of three
days and without hepatic and (or) pancreatic diseases as de-
termined by standard laboratory tests, medical history, and
physical examination.
After initial blood work, subjects received 100 mg thiamin
orally once a day for 30 days, 1 mg folic acid orally once a
Tm
day for 7 days, and 1 multi-vitamin (Stresstabs 600 Advanced
Formula High-Potency Stress Formula Vitamins, Lederle Labora-
tories Division, American Cyanamid Company) once a day for 30
days. Four hundred meg folic acid and 12 meg vitamin B-12 (as
cyanocobalamin) , two variables studied in this investigation,
were included in the multi-vitamin preparation.
After obtaining informed consent the subjects were ran-
domly assigned to one of two treatment groups; disulfiram or
placebo for 21 days. Nutritional assessment measurements and
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laboratory tests were performed at the beginning and end of the
21-day study period.
Study Medication
The study medication and placebo were prepared by the
hospital pharmacy. Disulfiram was prepared daily for oral ad-
ministration by pulverizing and dissolving the treatment dose
(Antabuse tablet-250 mg disulfiram) in 4 oz of canned unsweet-
ened orange juice (Juice Bowl Products, Inc.). Subjects in the
placebo group received 4 oz unadulterated canned unsweetened
orange juice. Study medication (or placebo) was taken under
supervision and neither the subject nor the nursing staff were
aware of who received disulfiram or placebo.
Nutritional Assessment
Dietary History
A dietary history including 24-hour diet recall, food fre-
quency, socioeconomic variables, known food allergies and (or)
intolerances, and nicotine and alcohol use, was taken at the
beginning of study participation. Adequacy of recent dietary
intake (24-hour recall) was estimated using the revised Daily
Food Guide (53).
Anthropometry
Anthropometric measurements including height, weight, mid-
arm circumference (MAC), triceps skinfold (TSF) , subscapular
skinfold (SSF), and thigh skinfold (THSF) were taken at the
beginning and end of the 21-day study period (54-57). All
measurements were taken by the same investigator; mid-arm
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circumference was obtained in cm from the right arm of each
subject, with an insertion tape (Ross Laboratories, Columbus,
OH) and skinfolds were measured in cm using a Lange Skinfold
Caliper (Cambridge Scientific Industries, Cambridge, MD; 57,
58). Mid-arm muscle circumference (MAMC) was calculated from
TSF and MAC as follows:
MAMC = MAC - (3.14 X TSF [in centimeters]).
A nomogram for calculation of total body fat in males was
used to estimate percent body fat from right side SSF and THSF
measurements (59). Weight, expressed as percent of ideal body
weight (%IBW) was evaluated against age and sex-specific refer-
ence values based on HANES II, 1971-1974 (56). Triceps skin-
fold, MAC, and MAMC were evaluated against standards reported
by Blackburn et al. (56), Bishop et al. (58), Bishop and
Ritchey (60), and Frisancho (61).
Data collection
Questionnaires and assessment forms were designed for the
specific needs of this investigation following the guidelines
of Roe (35), Grant (57), Christakis (62), and Aronson and
Fitzgerald (63). Interviews and data collection were conducted
using techniques developed for the "reluctant" or stigmatized
client (i.e., alcohol and drug dependent; 44,64,65). When
possible, obtained data was verified against the nutritional
summary taken by the admitting staff and (or) confirmed by
relatives
.
Laboratory Tests
The following parameters were obtained on fasting blood
22
samples obtained at the beginning and end of the 21-day study
period for each patient: total leukocyte count (WBC), mean
corpuscular volume (MCV), hematocrit (Hct), hemoglobin (Hgb),
total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), trigly-
cerides (TG), calcium, phosphorus, albumin, total protein (TP),
glucose, gamma-glutamyl transferase (GGT), folate, and cobala-
min (vitamin B-12).
Total leukocyte count, MCV, Hct, and Hgb were measured
on the ELT-8 laser-automated cell counter (Ortho Diagnostic,
Rariton, NJ) . The Abbott-VP (Abbott Industries, Irving, TX)
was used for enzymatic assay of serum TG , calcium, phosphorus,
albumin, TP
,
glucose, and GGT. Lipoprotein HDL-C (alpha) and
LDL-C (beta) fractions were separated by the micro-affinity
column chromatography method developed by Bentzen et al.(66;
Isolab Inc., Akron, OH). Total cholesterol (serum cholesterol
assays between the CO-VMAC laboratory and the Kansas State
University Food and Nutrition laboratory were not significantly
different and were highly correlated; r = 0.985, p <0.0001),
HDL-cholesterol, and LDL-cholesterol were determined enzymati-
cally (modified Sigma Procedure No. 351, Sigma Diagnostics,
St. Louis, MO). Percent recovery of lipoprotein fractions wa
calculated as follows:
HDL-C (mg/dl) + LDL-C (mg/dl)
% Recovery = ________. X 100
TC (mg/dl)
Serum folate and vitamin B-12 were determined by radio-
57 125
assay using a dual isotope ( Co and I) kit produced by
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Clinical Assays, Travenol Laboratories, Inc., Cambridge, MA.
Purified porcine intrinsic factor and exogenous folate binding
protein in bovine milk were utilized to bind free vitamin B-12
and free folate. Samples were counted for 1 minute in a multi-
channel gamma counter (Isodata, Inc., Rolling Meadows, IL).
Serum collected for folate and vitamin B-12 assay was protected
from the light both during freezing and storage.
Analysis
The experiment was carried out as a double-blind com-
pletely randomized design with a 2 x 2 factorial combination
(2 treatment groups and 2 measurement times). Analysis of
Variance (ANOVA) was used to compare initial and final meas-
urements and the difference between these measurements (final -
initial). A general linear model (Statistical Analysis System;
67) was utilized for ANOVA least squares means and means sepa-
ration (least significant difference).
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Results
Thirty-one male alcoholics without overt hepatic or pan-
creatic involvement completed the study. The mean age was 39.5
+/- 10.9 years and average years of alcohol abuse 12.6 +/- 6.9.
Fifteen subjects received disulfiram (250 mg/ day) and 16 re-
ceived placebo (controls). Twelve of the disulfiram group and
thirteen of the control group received vitamin/ mineral supple-
mentation.
Nutritional Status
Anthropometric measurements
Average (mean +/- SD) skinfold measurements compared to
age/sex specific data from the Health and Nutrition Examination
Survey (HANES, 1971-1974; 54) were within acceptable range
(85.8-102.5% of standard) at baseline and end of study. Ini-
tial and final mean percent of ideal body weight and body fat
were within acceptable range with the exception of percent body
fat in the control group (65.7-70.7% of standard). Analysis
utilizing least squares means (LSM) estimates to minimize
standard errors and decrease bias, showed no significant
(p<0.05) differences (initial-final, I-F) between or within
groups (Table I).
Dietary History
Socioeconomic and Abuse History
The disulfiram group had a significantly (p < 0.01)
higher mean income (12533 +/- 9181 vs. controls 6887 +/- 6811
dollars per year) than the control group. Analysis (LSM) of
other variables (employment, years of education, years of al-
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TABLE I Anthropometric values of subjects. Initial (I) and
final (F) values as means +/- SD.
Treatment 1 Treatment 2 Differences Standard
Variable (Antabuse) (Placebo) Between Values*
Groups(LSM) (male 35-
n = 15 n = 16 (p<0.05) 45 years)
Age (years) 43.4 +/-10.0 35.9 +/-11.0 NS
Body Weight I 71.2 +/- 7.5 69.9 +/- 9.2 NS
(Kg) F 74.3 +/- 7.7 71.4 +/- 8.4 NS
Ideal Body (acceptable range)
Weight (%) I 93.8 +/-13.1 91.8 +/-12.0 NS 80-120
F 98.0 +/-12.7 93.8 +/-11.1 NS
Body Fat (%) I 11.5 +/- 5.7 9.2 +/- 4.0 NS 14-22
F 12.6 +/- 5.2 9.8 +/- 3.9 NS
% of Std.+ I 82.1 65.7
F 90.0 70.0
(50th percentile)
Triceps I 12.0 +/- 4.8 10.3 +/- 4.7 NS
Skinfold (mm) F 12.3 +/- 3.7 11.4 +/- 5.4 NS 12.0
% of Std. I 100.0 85.8
F 102.5 95.0
Mid-Arm I 30.2 +/- 2.5 29.7 +/- 2.1 NS 32.7
Circumference F 30.7 +/- 2.6 30.3 +/- 1.6 NS
(cm)
% of Std. I 92.3 90.8
F 93.9 92.7
Mid-Arm Muscle
Circumference I 26.4 +/- 1.6 26.4 +/- 1.6 NS 28.7
(cm) F 27.2 +/- 2.2 26.6 +/- 1.6 NS
% of Std. I 91.9 91.9
F 94.8 92.7
* Standard values; Bishop, Bowen, and Ritchey (58), Sloan and
de V Weir (59), Frisancho (61), and Pike and Brown (68).
+ Acceptable % of standard, 80-120%
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cohol abuse, years of tobacco use, quantity of tobacco used
per day) did not reflect any significant differences between
groups (Table II).
Dietary Intake
Estimation of recent dietary intake obtained by 24-hour
recall (expressed as percent of recommended daily intake) in-
dicated no significant difference between groups. Mean percent
of recommended intake prior to admittance: Disulfiram group,
52.5 +/-34.9% vs. placebo group, 51.4 +/-24.1%.
Laboratory Tests
Hematology
Mean hematocrit values were within normal limits, however,
mean hematocrit was significantly lower in the control group
(p<0.01) on analysis (LSM) of I-F (disulfiram, 47.9 +/-4.5 to
48.6 +/- 3.3 4%; control, 48.2 +/- 2.7 to 46.4 +/-2.6%).
Baseline and final hemoglobin and total leukocytes (means +/-
SD) values were within normal limits with no significant dif-
ferences between treatment groups at p<0.05 (Table III).
Mean Corpuscular Volumn (MCV), an accepted marker for al-
coholism (69), was slightly elevated in both groups at baseline
and in the disulfiram group during final testing. On analysis
(LSM), there were no significant differences at p<0.05 within
or between groups (Table III).
Blood (Serum) Studies
As judged by the following laboratory tests: gamma-
glutamyl transferase, serum albumin, total protein, glucose,
triglycerides, calcium, and phosphorous, the two groups were of
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TABLE II Socioeconomic and abuse history factors affecting
nutritional status. Values as means +/- SD.
Treatment No.l Treatment No. 2 Differences (LSM)
Variable (Antabuse , n=15) (Placebo, n=16) Between Groups
(p< 0.05)
Unemployed (%) 60.0 43.7 NS
Education (years) 12.9 +/- 2.4 12.3 +/- 0.7 NS
Income ($) 12533 +/- 9181 6887 +/- 6811 p < 0.02
Alcohol Abuse 14.4 +/- 7.1 11.0 +/- 6.6 NS
( years)
Tobacco smok-
ing (years) 25.1 +/-13.5 20.8 +/-11.8 NS
(packs/day) 1.6 +/- 0.7 1.7 +/- 0.6 NS
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similar overall nutritional status (mean values +/- SD) both at
baseline and completion of the study. Difference in final glu-
cose levels between groups was significant at p<0.02 (disul-
firam, 95.2 +/-13.8 mg/dl vs. controls, 87.6 +/- 5.5 mg/ dl).
But, there was no significance within groups on analysis of I-F
serum levels (Table III).
Serum Cholesterol Levels . Total serum cholesterol levels
were assayed using two methods for control of accuracy (Abbott
VP, and modified Sigma Procedure No. 351; 66). Values were
verified by analyzing significance of correlation (initial,
r = 0.985, p< 0.0001; final, r = 0.992, p< 0.0001) between
assay methods. Results from the modified Sigma procedure are
reported in Table III.
Initial difference of means between treatment groups was
significant at p<0.04 (disulfiram, 203.0 +/- 34.6 mg/dl vs.
control, 174.5 +/- 30.1 mg/dl), indicating a slight biasing.
Subjects taking 250 mg disulfiram per day for 21 days had a
significant (p< 0.002) increase in total serum cholesterol
(203.0 +/- 34.6 mg/dl to 225.8 +/- 27.1 mg/dl). Control values
increased from 174.5 +/-30.1 mg/dl at baseline to 178.0 +/-
29.5 mg/dl at three weeks but the increase was not significant
(p<0.70). Final serum levels between groups were significant
at p<0.0002 (Figure I).
High-Density Lipoprotein Cholesterol . Initial and final
(mean +/- SD) serum values of high-density lipoprotien choles-
terol (HDL-C) were within normal limits for both treatment
groups (Table III). The expected decrease with cessation of
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TABLE III Laboratory values of subjects. Initial (I) and
final (F) values as means +/- SD.
Treatment 1 Treatment 2 Differences Normal
Variable (Antabuse) (Placebo) Between Values*
Groups(LSM) (male; 35-
n=15 n=16 (p< 0.05) 44 years)
Hematology ^
Hemoglobin ' I 15.3 +/- 1.0 15.5 +/- 0.8 NS 14.0-18.0
(gm/dl) F 15.8 +/- 0.6 15.4 +/- 0.8 NS
Hematocrit I 47.9 +/- 4.5 48.2 +/- 2.7 NS 42-52
(%) F 48.6 +/- 3.3 46.4 +/- 2.6 NS+
T. Leukocytes I 8.2 +/- 1.9 7.9 +/- 1.7 NS 5.0-10.0
(cumm X10) F 9.1 +/- 2.7 9.1 +/- 2.7 NS
MCV I 97.7 +/- 5.0 95.6 +/- 7.4 NS 80-94
(cuu) F 95.7 +/- 2.6 92.4 +/- 5.5 NS
Blood Studies-
GGT I 100.5+/-129.7 38.6 +/-31.5 NS 11-63
(IU/1) F 43.8+/- 42.8 27.1 +/-13.6 NS
S. Albumin I 4.4 +/- 0.3 4.5 +/- 0.4 NS 3.0-5.2
(gm/dl) F 4.5 +/- 0.4 4.5 +/- 0.4 NS
T. Protein I 7.3 +/- 0.8 7.2 +/- 0.5 NS 6.0-8.5
(gm/dl) F 7.2 +/- 0.4 7.2 +/- 0.3 NS
Glucose I 93.9 +/-11.7 91.2 +/- 7.9 NS 65-110
(mg/dl) F 95.2 +/-13.8 87.6 +/- 5.5 p<0.02++
TG I 141.7 +/-57.8 108.3 +/-42.3 NS 20-200
(mg/dl) F 127.6 +/-34.0 121.3 +/-46.1 NS
TC I 203.0 +/-34.6 174.5 +/-30.1 p<0.04 140-280
(mg/dl) F 225.8 +/-27.1 178.0 H-/-29.5 p<0.0002
HDL-C I 50.4 +/-13.3 56.8 +/-14.8 NS 29-61
(mg/dl) F 48.2 +/- 6.6 46.1 +/- 7.6 NS
LDL-C I 138.4 +/-21.2 107.8 +/-31.7
(mg/dl) F 160.7 +/-19.8 119.8 +/-29.3
Calcium I 9.5 +/- 0.5 9.5 +/- 0.4
(mg/dl) F 9.5 +/- 0.3 9.5 +/- 0.3
Phosphorus I 3.5 +/- 1.0 3.3 +/- 0.8
(mg/dl) F 3.7 +/- 0.6 3.8 +/- 0.6
* Normal Values specific to method used in determination of
serum values.
+ Hct. was significantly lower in the control group (P< 0.01) on
analysis (LSM) of I-F. ++ NS on analysis of I-F (LSM).
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Fig. I Total serum cholesterol of alcoholic patients receiving Antabuse,
250 mg/day (—————, n = 15) or placebo (-----, n 16) for a 21 -day
treatment period. Means with different superscripts differ significantly,
p<0.05. * Values significantly (p<0.0002) increased above baseline, day 0.
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alcohol intake (disulf iram, 50.4 +/- 13.3 to 48.2 +/- 6.6 mg/
dl vs. control, 56.8 +/- 14.8 to 46.1 +/- 7.6 mg/dl) showed no
significance at p<0.05 between or within groups during either
trial (Figure II).
Low-Density Lipoprotein Cholesterol . Subjects receiving
disulfiram (250 mg day) evidenced a marked increase in serum
low-density lipoprotein cholesterol fraction (LDL-C) over
the three week test period (increase: disulfiram, 22.3 +/-
19.4 mg/dl vs. control, 12.0 +/- 17.7 mg/dl). Initial LDL-C
mean values between groups were significant at p<0.009 indi-
cating a slight bias effecting LDL-C as well as total cho-
lesterol. Final (21 days) LDL-C differences (LSM) between
treatment groups were significant at p<0.0002 (Figure II).
Over the 21 day period there was a significant positive
correlation between increase in serum total cholesterol and
increase in LDL-C (r = 0.879, p<0.0001) indicating the possi-
bility of increased LDL-C fraction with disulfiram treatment.
The effect of disulfiram on LDL-C final values was significant,
but differences in repeated measures were not significant at
p<0.05.
Vitamin Studies
Serum Folate . Vitamin and mineral supplementation sig-
nificantly increased (p<0.002) the serum folate levels over the
three week treatment period in both groups (disulfiram, 5.3 +/-
1.7 to 11.4 +/- 6.9 ng/ml; placebo, 8.6 +/- 5.1 to 12.0 +/-
3.9 ng/ml). Mean values between treatment groups not receiving
folic acid therapy were without statistical significance during
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Fig. II Serum low-density lipoprotein (LDL) cholesterol and high-density
lipoprotein (HDL) cholesterol of alcoholic patients receiving Antabuse, 250 mg/
day ( , n = 15) or placebo ( , n = 16) for a 21-day treatment
period. Means with different superscripts differ significantly, p<.0.05.
initial and final trials. However, serum folic acid levels
decreased during the treatment period with the placebo group
falling below normal values (7.9 +/- 1.6 to 6.3 +/- 0.5 ng/ml)
of 7-19 ng/ml (Table IV). Interactions between groups (ANOVA 4
X 2 factorial) expressed as means are plotted on Figure III.
Serum Cobalamin . Mean increase of serum cobalamin was
markedly lower in the placebo group (n=13) receiving 12 meg
vitamin B-12 (as cyanocobalamin) during the 21-day treatment
period (354.6 +/- 134.3 to 373.2 +/- 373.2 pg/ml). Disulfiram
treatment group without cobalamin therapy (n=3) evidenced the
greatest increase of serum cobalamin (379.3 +/- 110.6 to 446.1
+/- 15.0 pg/ml). Slight biasing possibly due to low sample
size (Table IV).
Initial and final differences between groups were not
significant at p<0.05. Final-initial difference expressed as
means within groups were not significant (Figure IV).
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TABLE IV Serum Folate (ng/ml) and Cobalamin (pg/ml) concentra-
tions in subjects. Initial (I) and final (F) values as
means +/- SD.
Variable
Treatment 1
(Antabuse)
Treatment 2 Differences Normal
(Placebo) Between Groups Serum
(LSM, p<0.05) Values*
Without
Folic Acid
Therapy
(ng/ml)
Folic Acid
Therapy +
(ng/ml)
n=3
I 14.2 +/- 13.8
F 9.3 +/- 2.8
n = 2
7.9 +/- 1.6
6.3 +/- 0.5
n=12 n=12
I 5.3 +/- 1.7 8.6 +/- 5.1
F 11.4 +/- 6.9 12.0 +/- 3.9
F-I (difference within groups)
NS
NS
NS
NS
p<0.002
7-19
Without
Cobalamin
Therapy
(Pg/ml)
Cobalamin
Therapy+
(pg/ml)
n=3
I 379.3+/-110.6
F 446.1+/- 15.0
n=3
322.6+/-113.4
379.6+/-101.6
n=12 n=13
I 379.9+/-144.8 354.6+/-134.3
F 442.7+/-121.0 373.2+/- 92.8
F-I (difference within groups)
NS
NS
NS
NS
NS
200-900
* Normal values; Fishbach (51)
+ One mg folic acid orally once a day for 7 days; 1 multi-vitamin
including 400 meg folic acid and 12 meg vitamin B-12 (as cyano-
cobalamin, Stresstabs (R) 600 Advanced Formula, High-Potency
Stress Formula Vitamins, Lederle Laboratories Division,
American Cyanamid Company, Pearl River, NY) once a day for 30
days.
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Discussion and Conclusions
This study has investigated the possible effects of short-
term (3 week) disulfiram treatment on the overall nutritional
status of abstaining alcoholics in a controlled environment.
Special emphasis was placed on the effect of disulfiram treat-
ment on serum cholesterol, folate, and cobalamin levels.
The overall nutritional status of the subjects at baseline
demonstated no significant difference in the prevalence of mal-
nutrition when compared to the general population (percent of
alcohol abuse unknown). The current investigation supports the
findings of Halsted (40), Dickson et al.(41), and Bienia et al.
(70) which report no significant differences between alcoholic
and nonalcoholic groups in relation to incidence of malnutri-
tion (alcoholic, 36.9%; nonalcoholic, 43.7%; 70).
All study participants were offered the same (2500 calo-
rie) hospital diet. Over the three week treatment period all
anthropometric indices increased slightly in both treatment
groups as recorded in Table I. Slight increase in all values
indicates a refeeding effect (Lieber, 39) with no significant
effect from disulfiram treatment or vitamin therapy.
Mogens, Mogens, and Smith (15) report that tryptophan, one
of the amino acids recommended for nutritional support in de-
creased albumin synthesis, has been found to exhibit increased
clearance in individuals receiving disulfiram therapy. Serum
albumin and total protein were within normal limits at baseline
and termination of study participation in all of our subjects,
although, Mendenhall et al (43) found that 62% of patients
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studied, without liver disease, evidenced some type of protein-
calorie malnutrition.
Our current findings corroborate results from animal stud-
ies by Rothschild, Oratz, and Schreiber (45) indicating that
serum albumin is severly depressed only during liver involve-
ement and malnutrition. Disulfiram administration (250 mg/day)
did not appear to contribute to overt changes in serum albumin
or total protein during the 3 weeks treatment period.
Eisenstein (7) cited alcoholic hypoglycemia and hypergly-
cemia as possible results of alcoholism. Williams (36) report-
ed impaired hepatic glucose output in animals with excessive
alcohol intake and Arkey, Veverbrants, and Abramson (37) found
that hypoglycemia could be induced in healthy adult males given
15% ethyl alcohol infusions. No hypoglycemic or hyperglycemic
effect was found in either treatment group in our study. The
group receiving disulfiram had a slight increase in glucose
levels during the treatment period (93.9 +/-11.7 to 95.2 +/-
13.8 mg/ dl) and controls a slight decrease, representing a
possible trend. Futher investigation is needed on the effects
of disulfiram on glucose levels since disulfiram has been shown
to (1,5,14,23) decrease norepinephrine and epinephrine through
suppression of dopamine-B-hydroxylase (DBH) and may have an
effect on other regulatory hormones.
Prolonged disulfiram therapy in human and animal subjects
results in an elevation of serum cholesterol levels (1-3,5,6,9,
11-17,26,32,35). These studies frequently employed disulfiram
dose levels of at least 500 mg/day over a period of several
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months to years. We were challenged by these findings to
examine the possible effects of a therapeutic dose (250 mg/day
disulfiram) during initial treatment of alcoholism (21 days).
In a similar study to ours (disulfiram dosage and length
of treatment) Major and Goyer (12) reported a significant
elevation in total serum cholesterol levels after 3 weeks in
patients receiving 500 mg of disulfiram a day (p<0.02). An
elevation in serum levels was observed after 6 weeks in pa-
tients (n=8) receiving 250 mg daily, however, no significant
changes were observed at 3 weeks. Results of their study sug-
gest that initial disulfiram treatment (3 weeks) of 250 mg/day
has no significant effect on serum cholesterol.
In contrast, serum cholesterol levels in our subjects
receiving 250 mg disulfiram daily increased significantly
(p<0.002) over the 3 week treatment period; final serum
levels between groups were significant at p<0.0002 (Figure
I). Difference of means between treatment groups at baseline
was significant at p<0.04 representing a slight biasing.
This variation may have been due to not completely random
sampling; difference in mean age between groups (disulfiram,
43.4 +/- 10.0 years vs. controls, 35.9 +/- 11.0 years) and
years of alcohol abuse (disulfiram, 14.4 +/- 7.1 years vs.
controls, 11.0 +/- 6.6 years).
Dietary intake of cholesterol was not monitored in our
study but Rogers and Naseem (17) reported a twenty-five percent
increase in serum cholesterol with no variance of dietary in-
take between groups, after administration of disulfiram (15 mg/
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kg of body weight/day) to Sprague-Dawley rats. These investi-
gators observed a four-fold elevation in hepatic 3-hydroxy-3-
methyl-glutaryl co-enzyme A (HMG-CoA) reductase in the disul-
firam group, suggesting alteration in cholesterol synthesis.
We found very poor correlation between years of alcohol
abuse and serum high-density lipoprotein cholesterol (HDL-C) at
baseline (r = 0.232, p<0.20). But, our findings agreed with
those of Taskinen et al. (30), Marth et al. (31), and Devenyi
et al. (32) that HDL-C levels fall to normal levels within
three weeks of abstinence. Initial and final HDL-C levels were
within normal range in both treatment groups.
Hegarty et al . (71) and Willet et al. (72) report a sig-
nificicant depression of HDL-C serum levels in both animal and
human studies (p<0.05) with cigarette smoking. We found low
correlation between initial serum HDL-C levels and years of
smoking (r = 0.382) and quantity smoked (r = 0.170). Changes
in HDL-C levels (I-F) were not significant in the disulfiram
group and frequency of cigarette smoking did not change between
trials, indicating that initial HDL-C levels and subsequent de-
crease were directly related to alcohol use.
Increased levels of low-density lipoprotein cholesterol
(LDL-C) in workers exposed to toxic amounts of carbon disul-
fide, a final metabolite of disulfiram, have been reported
(12). Our findings from investigation into the short-term
effects of disulfiram on LDL-C levels support these results.
The group receiving disulfiram had a two-fold increase
of LDL-C over the control group (p<0.0002) suggesting that the
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effect of disulfiram on this fraction is immediate and may
contribute to hypercholesterolemia. During disulfiram treat-
ment (21 days), a positive correlation between increases
in total cholesterol and LDL-C was significant (r = 0.879,
p<0.0001). Again, similar to values of total cholesterol,
we found slight biasing at baseline between groups (p<0.009),
which may be a result of random variation. These findings
prompt further investigation with more repeated measures.
Concurrent with the effect of carbon disulfide on LDL-C
is the reported effect on pyridoxine (12-15), resulting in a
pyridoxine deficiency. We did not assay serum pyridoxine
levels in our subjects. Therefore, we are unable to draw
any conclusions on the relationship between pyridoxine and
increased LDL-C levels with initial disulfiram treatment.
Initial mean serum folate levels across all treatment
groups were within normal range. However, in agreement with
Mills et al. (47) who reported low levels of serum folate in
43% of patients studied, 19 subjects had an initial serum
folate below normal range.
We did not find any significant effect from disulfiram
therapy on serum folate status. Our findings of decreased
levels of serum folate without supplementation support the
hypothesis of Mills et al. (47) that a cyclic effect may occur
with chronic alcohol use whereby folate malabsorption promotes
folate deficiency resulting in intestinal malabsorption of
folate.
Pernicious anemia is not commonly found in alcoholics
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(35,49,52) but, vitamin B-12 deficiency can contribute to
folate deficiency through the methyl-f olate trap. Only one
subject had an initial blood profile symptomatic of overt al-
cohol related anemia: Serum folate, 5.64 ng/ml; serum cobal-
amin, 50.6 pg/ml; mean corpuscular volume (MCV), 101.0 cuu.
These findings do not agree with Lindenbaum and Roman (49) who
reported 62% of 65 alcoholic patients presenting with anemia.
Mean increase of serum cobalamin was not significant with-
in or between any treatment groups (disulfiram, placebo; with
cobalamin supplementation, without cobalamin supplementation).
The group receiving disulfiram and no supplementation had the
greatest increase over the 21 day treatment period. These re-
sults reflect possible biasing as a result of low sample size
(n = 3).
In conclusion, the nutritional status of the alcoholic
patients in this study was not compromised by either their
prior alcoholic intake or the 21-day treatment with disul-
firam. Neither serum folate nor serum cobalamin levels were
affected by disulfiram treatment. However, short-term (21-day)
treatment with a moderate dose (250 mg/day) of disulfiram did
produce a significant increase in total serum cholesterol and
an increase in low-density lipoprotein cholesterol fraction.
Because of the apparent effect of disulfiram on serum choles-
terol, the atherosclerotic risk may be increased in some
alcoholics treated with this drug.
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INFORMATION ABOUT
THE SHORT-TERM EFFECTS OF DISULFIRAM (ANTABUSE™) TREATMENT ON
NUTRITIONAL STATUS AND BLOOD CHOLESTEROL LEVELS IN ABSTAINING ALCOHOLICS
INFORMED CONSENT
—__________
_
Recent studies have suggested that elevation of total serum (blood)
cholesterol has been observed in some human subjects receiving disulfiram
(Antabuse) treatment to prevent alcohol intake while participating in
rehabilitation from alcoholism. At the same time, other effects that the
administration of disulfiram may have on nutritional status of the recover-
ing alcoholic are largely unknown.
The purpose of this study is to investigate the short-term effects of
disulfiram (Antabuse) treatment on total serum cholesterol, serum HDL-
cholesterol, and nutritional status of alcoholic patients during the in-
itial phase of abstinence from alcohol.
Your agreement to participate in this study will involve the
following:
1) willingness to be randomized (assigned by chance) into one of two treat-
ment groups. One group will receive 1 disulfiram (Antabuse) tablet (250
mg) and the other group will receive a placebo (inactive substance) each
day for 21 days. Subjects in both groups will receive all other benefits
associated with the Chemical Problems Treatment Unit (CPTU). All parti-
cipants will sign the Antabuse (disulfiram) Instructions and Consent
Form (VA form 10-63 R (677), August 1980).
2) access to your medical records for information pertinent to the study.
3) drawing of 30 ml of blood at the beginning and end of the study in addi-
tion to routine blood tests by the CPTU for biochemical and nutritional
evaluation. Nothing is to be taken by mouth except water for 12 hours
prior (7 P.M. to 7 A.M.) to drawing blood.
4) physical (anthropometric) measurements, i.e., height, weight, and skin-
fold measurements that will indicate the percent of body fat and muscle,
to be taken within 3 days of entering the CPTU and again after 21 days
continuous participation in the study, for evaluation of nutritional
status.
Total time required for participation in the study is approximately 3
hours over a 21 day period. You may contact any of the investigators to
answer any questions you may have at any point in the study.
Investigators - Roy B. Lacoursiere, M.D. Chemical Problems Treatment Unit
Phone: (913) 272-3111 Colmery-O'Neil Veterans Admini-
stration Medical Center
Topeka, Kansas 66604
Robert D. Reeves, Ph.D. Department of Foods and Nutri-
Phone: (913) 532-5508 tion
Kansas State University
Manhattan, Kansas 66506
Emmalyn B. Aiken Graduate Student
Phone: (913) 532-5508 Kansas State University
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Discomforts and Risks
If you will be taking disulfiram (Antabuse) there are some things
about it that you need to know. Like all medications, disulfiram (Antabuse)
may have certain side effects. Disulfiram ((Antabuse) may occasionally
cause drowsiness, tiredness, and skin eruptions. Although drowsiness is not
common with the dose of disulfiram (Antabuse) used in this study, we never-
theless urge you to be careful driving a car and working around machines or
in high places for the first serveral days after beginning the disulfiram
(Antabuse) treatment. If the medication causes drowsiness which persists
for more than a week or two, tell your counselor or doctor.
If you become a participant and receive disulfiram (Antabuse), it will
be necessary for you to AVOID ALL ALCOHOL. The reason is that disulfiram
(Antabuse) can cause a SEVERE REACTION WHEN TAKEN WITH ALCOHOL. If you
drink alcohol while taking disulfiram (Antabuse), you will get a reaction
consisting of flushing, headache, difficulty breathing, nausea, vomiting,
dizziness, and fainting. In severe reactions, heart attacks can occur, and
this could endanger your life. You must also avoid alcohol in medications
and food, and in cosmetics if your skin is very sensitive. If you stop the
disulfiram (Antabuse), you must wait up to two weeks before drinking any
alcohol
.
This study involves only minimal discomfort from drawing blood. The
primary discomfort will be the slight pain associated with drawing blood as
the sterile needle enters the skin. The staff drawing your blood are ex-
perienced and will minimize the discomfort as much as possible. Skinfold
measurements will be taken on the arm, shoulder, and thigh. No physical
pain is associated with this activity.
Benefits
This study will serve to increase the knowledge of the benefits and/or
hazards of administering disulfiram (Antabuse) treatment as a support to
reaching optimal physical and behavioral recovery from the illness of alco-
holism.
Alternative Actian and Confidentiality
You may withdraw at any time from participation in the study without
jeopardizing your treatment or other VA benefits. The investigators ask
that you meet with them if you wish to leave the study so that any mis-
understanding can be clarified. Your identity as a participant wi 11 not be
revealed in any published or oral presentation of the results of this
study.
For Non-Veteran or Non-Eligible Veteran Participants
"In the unlikely event you are injured as a result of participation in this
study, the Colmery-O'Neil VAMC is authorized to furnish humanitarian emer-
gency medical care only as provided by Federal Statute. Non-eligible veter-
ans might be entitled to compensation under 38 U.S.G. 351 or to recovery
under the Federal Tort Claims Act, depending on the circumstances of the
particular situation. Non-Veterans, however, can recover only in situations
where negligence occured, which would be covered by the provisions of the
Federal Tort Claims Act. For further information, contact the VA District
Legal Counsel at (316) 267-6311."
5A
For Veteran Participants
"In the unlikely event you are injured as a result of Participation in this
study, the Colmery-O'Neil VAMC will furnish medical care as provided by
Federal Statute. Compensations for such injury may also be available for
you in some instances, under the provisions of the Federal Tort Claims Act
(28-U.S.C. 1346 (B) and 2675). For further information contact the VA
District Legal Counsel at (316) 267-6311.
I, certify that the above written
summary was discussed and explained fully to me by one of the
investigators.
Date Subject's Signature
Date
Date
Investigator's Signature_
Witness
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Topeka Veterans Administration Medical Center
Chemical Problem Treatment Unit
Antabuse (Disulfiram) Instructions and Consent Form
As part of your treatment program you may want to start taking Antabuse, chemically
called disulfiram. Antabuse is a medicine that works by interfering with the way
your body handles alcohol after the alcohol gets into your system. Antabuse slows
the breakdown of alcohol at an intermediate stage, and a substance accumulates in
your body that causes the reaction. The reaction varies considerably, depending on
the amount of Antabuse in your body and how much alcohol is taken. Most of the symp-
toms are caused by enlargement of the skin blood vessels and a drop in blood pressure.
The mildest symptoms are a flushing of the skin with a feeling of heat. This is due
to the enlargement of the blood vessels in the skin. Some people experience little
more than this. Other symptoms that go with this and with the drop in blood pressure
include a feeling of weakness and nausea, headache, sweating, a strong heart beat,
and in more severe cases, vomiting and fainting. The reaction can be very severe,
especially with large amounts of alcohol and Antabuse. In very rare cases the
Antabuse-alcohol reaction has led to death.
On the dosage we usually prescribe, patients who drink alcohol on top of the Anta-
buse usually experience only a moderate amount of discomfort, but it depends on how
much alcohol is taken. This discomfort is enough to keep you from drinking accord-
ing to your old patterns. You won't be able to drink to feel good. You won't be
able to drink to get rid of anxiety or to get up your courage. You won't be able
to drink just to be friendly or because there doesn't seem to be any reason not to
drink. Antabuse will give you another reason to refuse a drink. If you take Anta-
buse in the morning that settles for the day the question of whether or not to drink.
When friends ask you to take a drink you will be able to tell them you are taking
Antabuse and if they still insist that you drink, you will know they are not your
friends
.
.
When taken daily Antabuse builds up in the body fluids and will remain in your body
for several days after you stop taking it. Some people have an Antabuse reaction
as much as a week or two after they stop taking Antabuse, if they drink alcohol.
This means that you can't stop taking Antabuse today and start drinking the old way
tomorrow. You have to wait several days, and hopefully in that period of time you
will control the urge to drink and start back on Antabuse. It is a kind of insur-
ance policy.
There are certain precautions that you have to take when you are on Antabuse. It
is very unusual for people to have any serious symptoms from Antabuse itself, but
occasionally patients will be drowsy when first on Antabuse, or develop a rash or
some other symptom while they are taking this medicine. Report any kind of symp-
toms you develop after you have started on the medicine. In addition you have to
be careful not to drink alcohol accidentally. You will react to alcohol in any
form, not only in alcoholic beverages. Years ago, when high doses of Antabuse
were used, some people claimed that they saw reactions due to alcohol rubs, but we
have seen no reactions to alcohol absorbed through the skin or through the lungs
with doses of Antabuse that you will be taking. However, in things that you eat
or drink, even in medicine, it is important for you to avoid alcohol. Any time a
doctor treats you, tell him that you are on Antabuse and that you cannot take any
medicine that contains alcohol. When you have prescriptions filled, also tell the
pharmacist that this is the case and that you must not have any medicine containing
alcohol. (For example, most cough and cold medicines contain large amounts of al-
cohol.) It is important for you not to drink from a punch bowl and not to take
drinks when you don't know what is in them. Even foods containing alcohol must be
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avoided unless you are certain that the alcohol content has been cooked out. The one
drug other than alcohol that might cause an Antabuse reaction is paraldehyde, so it
must also be avoided. (Paraldehyde is an old sleeping medication that is not used
very often anymore.) If at any time when you are on or going to take Antabuse and
you have any medical concerns about Antabuse and your taking it, discuss these with
your doctor. Also, for your safety, we will give you a card to carry with you that
says you are on Antabuse.
If you should have an Antabuse reaction, that is, if you should drink alcohol while
you are taking Antabuse, and then have some symptoms, it is likely that you will want
to discontinue your activities at the time, and you will probably want to lie down.
Most people will feel nauseated enough that they will want to have some kind of con-
tainer nearby in case they vomit. It is usual for someone with an Antabuse reaction
to lie down and finally fail asleep and to feel well when he or she awakens a few
hours later. Lying down is the best thing you can do, since this counteracts the
effects of the lowered blood pressure. Certainly while you are feeling ill you should
not try to do things like driving a car or climbing a ladder or other activities that
would endanger you or others because of your feeling of weakness and discomfort. If
a reaction makes you extremely ill, or if you become concerned, it would be appropri-
ate for you to call a doctor or go to a hospital emergency room. Do not try to drive
during a reaction. If you don't take any alcohol, you won't have a reaction .
It is a good idea to get used to a regular pattern in taking your Antabuse. Perhaps
you can combine it with some other activity that you rarely forget. If you are mar-
ried or have a family member or other helpful person with you regularly, it is a good
idea to take your medication at a time when they see you take it so that if you for-
get he or she can remind you about taking it each day. Also, by informing your spouse
or other close person(s) that you are on Antabuse, this will help them to not give you
anything to drink or eat containing alcohol. If you forget to take it at the regular
time you should take it when you do remember. Lots of people ask how long they will
have to stay on this medicine. We have discovered that most people don't like the
idea of being on medicine indefinitely, and decide in their own minds that they will
give this a brief trial. We recommend that you take the medication for one year, then
decide at that time if you should continue. In any case, we recommend that you talk
with your doctor or counsellor before you consider stopping your Antabuse.
Years ago people were given a "challenge." They were given alcohol after they were
started on Antabuse so they would experience an "Antabuse reaction." We don't see
any need for this. You have been told what will happen if you drink alcohol when
on Antabuse, and we think that is sufficient.
(If further questions should come up in your mind about Antabuse, please be sure
to ask about them.)
I,
,
hereby ask for and consent to Antabuse
(disulfiram) treatment as explained in this material and by Dr.
.
Witness Patient's Signature
Date
VA Form 10-63 (677)
August 1983
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APPENDIX B-
Assessment Forms
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NUTRITIONAL ASSESSMENT FORM - DISULFIRAM-NUTRITION
Date
Subject Code No. Date Admitted Age Sex
Education Occupation Income
Ethnic Background_ Marital Status
Number of persons living in household
Medical History:
Date of last examination before admittance and reason
Food Intolerance S/or Allergies^
Hyperlipidemia_
Cardiovascular Disease_
GI Disorders
History of Alcohol Intake_
History of Abuse Drug Intake
History of Prescription Drug Use_
Renal, Pancreatic Sc/qt Hepatic Disease_
Other diseases
Hospitalization (s) and Diagnosis_
Current diagnosis (s)
Current Symptoms and Clinical Signs (that may affect nutritional status)
Symptoms Clinical Signs
Anorexia__ Skin (dermatitis)
Vomiting; Eyes
Diarrhea Hair
Stomach Pain Teeth-Gums.
Excessive Fatigue Tongue
Peripheral Numbness, Tingling, Mouth-Lips_
or Pain
Loss of Taste Acuity
Nails
Neurological (confusion)
Other Other
Current Medication (s)
Vitamin/Mineral Supplements
Tobacco Smoking; Length of time
\
Quantity per day_
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Nutr. Assess., Contd. -2- Code No._
Dietary Information:
Current Diet Order
Trouble Chewing or Swallowing,
Review of Diet History (Food Frequencyi 24-hour recall, etc) expressed as total
percent of recommended intake for adult:
Foods Eaten % of Recommended/Day Comment
Meat, Fish or Poultry
Milk or Milk Products
Fruits 8c/or Vegetables
Breads Sc/or Cereals
Alcohol Containing Beverages
Total % of Recommended Intake
Daily intake of Coffee, Tea, Cola
Recent changes in food intake and meal planning.
Cultural/religous dietary practices
Vitamin/mineral supplements (taken before admittance)
Physical Activity (level) How often and what activities.
Food preparation and storage facilities
Who purchases and prepares food? Participation in Food Assistance
Programs? When?
NUTRITIONAL IMPLICATIONS OF PATIENT HISTORY (medical, socioeconomic, dietary):
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Nutr. Assess., contd. -3- Code
Initial
_Jo IBW
No.
Anthropometrics
:
Height Body Weight: Admitting (study)
Tpr-nination Ideal Body Weight(IBW) /
lYino-nR Skinfold /
_J> Std. /
Mid Arm Circumference / _J> Std. /
Mid Arm Muscle Circumference / _Jo Std. /
Siih^narmlar Skinfold /
_J> Std. /
Thigh Skinfold /
_J Std. /
Rndy Vat. /
Laboratory Values
:
T«qt Initial'
_J, Std. /
Termination Normal
Hemoglobin U.0-18.0 gm/dl
Hematocrit 42-523
Total. Leukocytes (TLC) 5.0-10.0 X10
3
Mean Corouscular Volume (MCV)
3
80-94 unr
nr,T
,
,
11-63 IU/L
S. Albumin 3.0-5.2 srm/dl
Total Protein 6.0-8.5 fnn/dl
Fasting Glucose (blood) 65-110 me/dl
Triglycerides 20-200 me/dl
Total cholesterol _
._ .
UO-280 msc/dl
HDL-cholesterol 29-61 mff/dl
LDL-cholesterol 66-178 me/dl
Calcium 8.5-10.5 ag/dl
Phosphorus 2.5-4.5 mg/dl
Serum Folate 7-19 ne/ml
Cobalamin (B-12) 200-900 D£r/ml
NUTRITIONAL IMPLICATIONS OF PHYSICAL EXAM (anthropometrics, clinical findings):
62
Nutr. Assess., contd. -4- Code No._
NUTRITIONAL IMPLICATIONS OF LABORATORY VALUES:
NUTRITIONAL IMPLICATIONS' OF DRUG-NUTRIENT INTERACTIONS:
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DISULFIRAM-NirailTIOH STUDY
DIET HISTORI FORM
CLIENT NO.
24-HOOR RECALL
Date Time Food/Amount Where With Whom Associated Activity
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DHx -2- (D/u'S)
Trouble chewing or swallowing.
Meal times (usually) AM PM_
Snacks What times?
Recent changes in food intake or meal patterns.
Vitamins/mineral supplements How Often?,
Why?
"Health foods", dietetic foods or convenience foods
__
How often and why?
Cultural/religious dietary practices.
Food preparation and Storage facilities.
Who purchases and prepares food?
Storage time of fresh fruits and vegetables,
s
How prepared?
What type of cooking utensils used?_
Pried foods Frequency
Participation in Food Assistance Program(s)
Physical activity.
What periods of your life have you been overweight?.
Overweight relatives
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Meals eaten away from home Where? How often?
Wt. Wt.,10 years Wt,, 20 years Desired Wt,.
Maximum Wt.(age
<) Minimum Wt. (age)
How often and what activity?
Hobbies/recreational activities
DHx -3- (D/foS)
Do you include the following foods in the diet every day?
2 servings meat, fish, or poultry-
2 servings milk or milk products_
A servings fruits and vegetables (vitamin C),
U servings breads and/or cereals
2 servings butter, margarine or oil_
Additional comments:
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FOOD FREQUENCY SCHEDULE - DISULFIRAM-EUTRITION STUDY
Client No.
___
FOOD
DON'T
EAT
DO EAT
times/day times/week
I. MEAT GROUP
Chicken
'
Beef, hamburger, veal
Liver, kidney, tongue, Etc.
-
Lamb
Coldcuts, hot dogs
Fork, ham, sausage
Bacon
Fish
Kidney beans, pinto beans,
lentils (all legumes)
Soybeans
Eggs
Nuts or seeds
Peanut butter
Tofu
H. MILK GROUP
Milk (fluid, dry, evaporated).
Cottage Cheese
Cheese, all kinds other than
cottage
! Condensed milk (sweetened)
Ice cream
Yogurt
Pudding and custard
Milk shake
Sherbet
Tee milk
III. BREAD AND CEREAL GROUP
Whole grain bread
White bread
Rolls, biscuits, muffins 1
!
Bagel i
1
L
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FSS,2
FOOD
DON'T
EAT
DO EAT
TIMESA>AX TTMERAnrejr
Crackers, pretzels
Pancakes, Waffles
Cereals (cooked or dry)
White rice
Brown rice [
Noodles, macaroni, grits .}
Tortillas (flour)
Tortillas (corn)
Corn
Sweet potato or yam
. Green (sweet) peas
Lima beans
Hominy
Cakes, pies, cookies
f
Sweet rolls, doughnuts I
IV. FRUITS AND VEGETABLES |
Tomato or tomato juice
Stewed tomato or tomato sauce
Orange or orange juice
Tangarine
Grapefruit or grapefruit juice
i Mango, avacado
Lemonade :
Turnip
Peppers (green, red, chili)
Strawberries
Dark green or red lettuce
Asparagus
Swiss Chard
Bok Choy
Cabbage
Broccoli
Brussels sprouts
Onions
Scallions
i
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FSS,3
FOOD
DON'T
EAT
DO EAT
TIMES/DAI TIMES/WEEK.
Spinach
Greens (beet, collard, kale,
m twenty mustard)^
Carrots
Artichoke
Zucchini
Summer squash
Green and wax beans
Beets
Cucumbers cr celery
Peaches
"""
Apricots
Apples
Bananas
Pineapple
Cherries
Plums
Dates
Raisins
V. OTHERS (MISCELLANEOUS)
Candy
Sugar or honey-
Carbonated beverages
Coffee or tea
.
Cocoa 1
Wine, beer, cocktails
Fruit drinks
Irish Potatoes (HOW PREPARED?)
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APPENDIX C-
Laboratory Procedure
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September 1984
CHOLESTEROL DETERMINATION (TOTAL, HDL, LDL) WITH MICRO-SCALE
AFFINITY CHROMATOGRAPHY, COLUMNS
Column separation of alpha and beta fractions per Isolab instructions
using Isolab columns and elution fluids.
Determination of cholesterol can be done with other enzyme methods as
long as samples are diluted correctly and the ratio of serum
to enzyme is maintained (appropriate to the reagent directions.)
Sigma quantitative, enzymatic determination of total and HDL cholesterol
in serum at 500nm (procedure No. 351)
Sigma procedure modified as follows:
1. Macro-method (greater than 1 ml reaction volume) for total
choldsterol used for all determinations so that Brinkmann
probe colorimeter could be used,
2. Total cholesterol serum -samples and standards (50 and 200mg)
diluted 1:6 to match dilution factor of alpha and beta
eluates.
i.e. 0.2 ml serum or standard
1.0 ml saline
1.2 ml total volume = eluate volume and concentration
3. Once all serum, eluates and standards are at similar dilution,
0.12 ml is added to 1.0 ml of reagent so that correct ratio
of serum to reagent is maintained (i.e. original Sigma
method: 0.02 ml serum to 1.0 ml reagent = 1:50, therefore,
diluted serum and standards use 0.12 ml (6x) to 1.0 ml
reagent = 1 : 50)
.
4. More consistent results obtained if reagent is reconstituted
(50 ml deionized water/bottle) several hours (or overnight)
before use.
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PROCEDURE: Separation of alpha and beta fractions (HDL and LDL cholesterol)
Isolab LDL-Direct Cholesterol Audit System
#QS-8160 (60 test)
Isolab Inc.
Innovative Biochemical Methodology
Drawer 4350
Akron, OH 44321 800-321-9632
Bentzen, C.L. , Acuff, K.J., Marechal, B. , Rosenthal, M.A. and Volk, M.E.
(1982) Direct determination of lipoprotein cholesterol distribution
with micro-scale affinity chromatography columns. Clin Chem 28(7):
1451-14S6.
1. Remove first the column's top cap, then the bottom closure.
This order of opening is important - otherwise air will
enter the column tip, interfering with free liquid flow.
2. Use the wide end of a Pasteur pipette to.push the upper disc
down until it contacts the top of the resin bed. Do not
compress bed.
3. Allow the column to drain until the liquid level reaches the
top disc, where flow will automatically stop.
4. Check to determine whether air may have entered the column
during shipment. A few small air bubbles will not affect
its performance. However,' large volumes of air should be
removed by tilting the top disc until the bubble escapes,
then returning the disc to its original position.
5. Equilibrate the column bed by adding 1.0 ml of Alpha Fraction
Elution Agent (Reagent #1) to the column. Allow column to
drain. Discard eluate.
6. With the column positioned over a test tube (12 x 75mm, 5 ml),
add 0.2 ml patient serum to the column, near or on the upper
disc. Collect the eluate.
7. Add 1.0 ml of Alpha Fraction Elution Agent (Reagent #1) and
collect the entire volume in the same test tube, for a total
fraction volume of 1.2 ml. Mix well.
8. Place the column over a clean 12 x 75 mm tube.
9. Add 1.2 ml of Beta Fraction Agent (Reagent #2) and collect the
entire volume. Mix well
Fill column^with saline or eluted Alpha Elution Reagent, recap
and store for possible regeneration.
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PROCEDURE: Determination of Cholesterol (total, HDL, LDL)
Cholesterol, Total and HDL Quantitative, Enzymatic Determination
in Serum or Plasma at 500 nm (Procedure No. 351). Cholesterol
Reagent, Catalog No. 351-50, 50 ml size
Sigma Diagnostics
P.O. Box 14508
St. Louis, MO 63178
800-325-3010 (order)
800-325-8070 (service and technical information)
Cholesterol Standards:
Dow Diagnostics
The Dow Chemical Company
Indianapolis, IN 46268
200 mg/dl- - 212688 lot # 3M4L
expiration Dec. 1985
50 mg/dl - 213967 lot # 3M4M
expiration Dec. 1985
Cholesterol in solution of ethylene glycol monomethyl ether and stabilizer
Procedure
Incubator at 37 C
Reagent should be reconstituted (50ml deionized distilled water/bottle)
several hours or overnight before assay.
Disposable glass tubes 12x77 mm (5 ml culture tubes)
A. Dilution of standards and serum for total cholesterol (1:6 to match
dilution of alpha and beta fractions during separation).
1. Pipette 0.2 ml of each STANDARD (50 and 200 mg/dl) or
SERUM SAMPLE for total cholesterol into tubes.
2. Add 1.0 ml SALINE to each of the above tubes and vortex.
Cholesterol Determination
1. Pipette 0.12 ml saline for blank (or distilled water)
0.12 ml diluted serum for total cholesterol
0.12 ml diluted standards
0. 12 ml alpha fraction
0.12 ml beta fraction
(run duplicates of each, except blank)
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•
Cholesterol Determination (continued)
•
2. To each tube add 1.0 ml cholesterol REAGENT
Cover with parafilm and invert several times to mix (gently)
3. Incubate all tubes at 37°C for 12-15 minutes.
4. Following incubation, add 1.0 ml SALINE to all tubes and
vortex gently, (can add 2.0 ml saline to increase volume to
3 ml to read in Spec. 20).
5. Read BLANK - 100% transmittance, 0% absorbance as reference
at 545 nm (direction indicate 500 +_ 15 nm but Brinkmann
probe has filter at 545nm). Read and record absorbance of
•STANDARD and SAMPLES.
COMPLETE ALL READINGS WITHIN 30 MINUTES OF INCUBATION
6. Calculate cholesterol as follows:
Absorbance^ .
Cholesterol (mg/dl) = jr r sample X Concentration ofADsorbance
Standard standard (50 or 200)
7. Calculate percent recovery of alpha and beta fractions:
HDL (mg/dl) + LDL (mg/dl)
% Recovery = X 100
Total Cholesterol (mg/dl)
(recovery generally 94-97%)
Ik
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Abstract
Disulfiram (tetraethylthiuram disulfide) is an alcohol-
sensitizing compound used to encourage the alcoholic to main-
tain abstinence while receiving primary therapy for alcoholism.
Several investigations have suggested that administration of
disulfiram in therapeutic doses (500 mg per day) may be associ-
ated with increased serum cholesterol levels and subsequent
increased risk for atherosclerosis and bilary complications.
However, little is known about the effects of disulfiram thera-
py on the nutritional status of the alcoholic. The
purpose of
this 21 day, double-blind study was to investigate the short-
term effects of disulfiram on the nutritional status and serum
cholesterol of abstaining alcoholics.
No significant changes in overall nutritional status were
observed in 15 male alcoholic subjects receiving 250 mg disul-
TM
firam (Antabuse ) daily for 21 days. Disulfiram treated sub-
jects had increased mean fasting blood glucose levels (93.9 to
95.2 mg/dl) while the placebo group (n=16) had a mean decrease
of 3.6 mg/dl, indicating the need for further investigation.
Serum folate increased significantly in all groups receiving
folate supplementation (p<0.002), but showed no effect from
disulfiram administration.
Administration of 250 mg of disulfiram per day increased
mean total serum cholesterol from 203.0 +/-34.6 mg/dl to 225.8
+/- 27.1 mg/dl (p <0.0002 between treatment groups) and mean
low-density lipoprotein cholesterol 138.4 +/- 21.2 mg/dl to
ii
160.7 +/-19.8 mg/dl (p <0.0002 between groups) after three
weeks. The increase in low-density lipoprotein cholesterol
was numerically equal to the increase in total serum choles-
terol, implicating that fraction in the elevation of total
cholesterol. Results from this study indicate an immediate
effect (first 21 days) on total serum cholesterol and low-
density lipoprotein cholesterol from disulfiram therapy with
possible increased risk of hypercholesterolemia and athero-
sclerosis.
iii
